Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - estradiol valerate; norethisterone - oral tablet - 2mg ; 1mg

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - estradiol valerate; norethisterone - oral tablet - 2mg ; 1mg

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (germany) - estradiol valerate; cyproterone acetate - oral tablet - 2mg ; 1mg

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - estradiol valerate; norgestrel - oral tablet - 2mg ; 500microgram

ABD - İngilizce - NLM (National Library of Medicine)

american regent, inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate injection is indicated in the: 1.    treatment of moderate to severe vasomotor symptoms associated with the menopause. 2.    treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause.  when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3.    treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4.    treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1.    undiagnosed abnormal genital bleeding. 2.    known, suspected, or history of cancer of the breast. 3.    known or suspected estrogen-dependent neoplasia. 4.    active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5.    active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial i

ABD - İngilizce - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate injection, usp is indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1.  undiagnosed abnormal genital bleeding. 2.  known, suspected, or history of cancer of the breast. 3.  known or suspected estrogen-dependent neoplasia. 4.  active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5.  active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial   infarction). 6.  live

ABD - İngilizce - NLM (National Library of Medicine)

xiromed, llc - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate injection, usp is indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection, usp should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - estradiol valerate injection, usp should not be used in patients with known hypersensitivity to its ingredients. - known or suspected pregnancy. there is no indication for estradiol valerate injection, usp in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions ).

Belçika - İngilizce - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - estradiol valerate 2 mg - coated tablet - 2 mg - estradiol valerate 2 mg - estradiol

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; povidone; purified talc; maize starch - oral contraception. treatment of heavy and/or prolonged menstrual bleeding in women without organic pathology who desire oral contraception.

ABD - İngilizce - NLM (National Library of Medicine)

par pharmaceutical, inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 10 mg in 1 ml - delestrogen (estradiol valerate injection, usp) is indicated in the: 1. treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). delestrogen should not be used in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of cancer of the breast. 3. known or suspected estrogen-dependent neoplasia. 4. active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5. active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). 6. liver dysfunction or disease. 7. delestrogen should not be used in patients with known hypersensitivity to its ingredients. 8. known or suspected pregnancy. there is no indication for delestrogen in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy [see precautions ].